Cardiac safety profile of ponatinib with its associated dosing and frequency of cardio-oncology referral over time. The reason for the decrease in incidence of CAEs since 2014 is multifactorial, including heightened awareness of cardiovascular risks, with ponatinib treatment leading to increased cardio-oncology referrals, shorter time to ponatinib dose reduction when clinically indicated, and lower starting dose. Pre-2014 patients with CAE(s): 10 of 37 (28.0%); post-2014 CAE(s): 8 of 14 (19.5%).